News Madrigal Pharmaceuticals, Inc.

Stocks

MDGL

US5588681057

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 10/06/2026 am IST			5-day change	1st Jan Change
476.89 ^USD	+2.06%		+5.31%	-18.11%

27/05	Madrigal Pharmaceuticals Says Data Show Rezdiffra Reduces Cardiovascular, Liver-Related Risks in MASH Patients	MT
27/05	Madrigal Pharmaceuticals Presents Data Demonstrating Rezdiffra Reduces Markers of Cardiovascular and Liver-Related Risk in Patients with Mash	CI

All News

Mentions Relevance

05/06	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)	AQ
03/06	Madrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026	AQ
27/05	Madrigal Pharmaceuticals Says Data Show Rezdiffra Reduces Cardiovascular, Liver-Related Risks in MASH Patients	MT
27/05	Madrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients with MASH	AQ
27/05	Madrigal Pharmaceuticals Presents Data Demonstrating Rezdiffra Reduces Markers of Cardiovascular and Liver-Related Risk in Patients with Mash	CI
26/05	Madrigal Pharmaceuticals Insider Sold Shares Worth $2,928,716, According to a Recent SEC Filing	MT
22/05	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)	AQ
20/05	Madrigal to Present New Data from the Company’s MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension Risk	AQ
20/05	Madrigal Pharmaceuticals Presents New Data On Rezdiffra At EASL 2026 Demonstrating Effects On Cardiovascular And Portal Hypertension Risk Markers	CI
13/05	Truist Raises Price Target on Madrigal Pharmaceuticals to $709 From $640, Keeps Buy Rating	MT
08/05	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)	AQ
06/05	Madrigal Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
06/05	Madrigal Pharmaceuticals, Inc., Q1 2026 Earnings Call, May 06, 2026
06/05	Madrigal Pharmaceuticals' Q1 Loss Widens, Revenue Rises	MT
06/05	Earnings Flash (MDGL) Madrigal Pharmaceuticals Posts Q1 Net Loss $3.25 a Share, vs. FactSet Est of $4.23 Loss	MT
06/05	Madrigal Pharmaceuticals : MDGL 1Q26 Earnings Presentation	PU
06/05	Earnings Flash (MDGL) Madrigal Pharmaceuticals, Inc. Reports Q1 Revenue $311.3M, vs. FactSet Est of $301.1M	MT
06/05	Madrigal Pharmaceuticals : 1Q26 Press Release Final	PU
06/05	Madrigal: Q1 Earnings Snapshot	AQ
06/05	Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates	AQ
05/05	Madrigal Pharmaceuticals Inc announces exclusive global license for Aro-Pnpla3 from Arrowhead	RE
05/05	Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline	AQ
29/04	Madrigal Pharmaceuticals, Inc. Announces Board Changes, Effective April 22, 2026	CI
22/04	Madrigal Pharmaceuticals to Release First-Quarter 2026 Financial Results and Host Webcast on May 6, 2026	AQ
22/04	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)	AQ